"Accelerated Heart Failure Medication Up-Titration Proven Effective in STRONG-HF Trial"

The STRONG-HF trial found that rapid dose titration of guideline-directed heart failure medications in recently hospitalized patients resulted in significant benefits and minimal safety concerns compared to usual care. Patients in the high-intensity group had a higher incidence of optimal doses of common guideline-directed therapies and a lower rate of heart failure readmission or all-cause death at 180 days. The study should be used as a framework for managing heart failure medications and providing close follow-up and monitoring within the first few weeks following hospitalization.